Abstract
Very soon after the discovery of radiation and radioactivity short- and long-term negative effects of radiation on human tissue were observed. Adverse effects of X-rays were observed by Thomas Edison, William J. Morton, and Nikola Tesla; they independently reported eye irritations from experimentation with X-rays and fluorescent substances. These effects were thought to be eye strain, or possibly due to exposure to ultraviolet radiation. Elihu Thomson (an American physicist) deliberately exposed the little finger of his left hand to X-rays for several days, for a short time each day, and observed pain, swelling, stiffness, erythema, and blistering in the finger, which was clearly and immediately related to the radiation exposure. William Herbert Rollins (a Boston dentist) demonstrated that X-rays could kill guinea pigs and result in the death of offspring when guinea pigs were irradiated while pregnant. Henri Becquerel received a skin burn from a radium source given to him by the Curies that he carried in a vest pocket at times. He once was reported to have said: “I love this radium but I have a grudge against it!” The first death in an X-ray pioneer attributed to cumulative overexposure was to C.M. Dally in 1904. Radiologists and other physicians who used X-rays in their practices before health physics practices were common had a significantly higher rate of leukemia than their colleagues. A particularly tragic episode in the history of the use of radiation and in the history of industrialism was the acute and chronic biological damage suffered by the Radium Dial Painters [1]. Radium was used in luminous paints in the early 1900s. In factories where luminous dial watches were made, workers (mainly women) would sharpen the tips of their paint brushes with their lips, and thus ingested large amounts of radium. They had increased amounts of bone cancer (carcinomas in the paranasal sinuses or the mastoid structures, which are very rare, and were thus clearly associated with their exposures, as well as cancers in other sites) and even spontaneous fractures in their jaws and spines from cumulative radiation injury. Others died of anemia and other causes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mullner R (1989) Deadly glow. The radium dial worker tragedy. American Public Health Association, Washington DC
Bergonie J, Tribondeau L (1906) De quelques resultats de la Radiotherapie, et esaie de fixation d’une technique rationelle. Comptes Rendu des Seances de l’Academie des Sciences 143:983–985
Jonah CD, Miller JR (1977) Yield and decay of the OH radical from 100 ps to 3 ns. J Phys Chem 81:1974–1976
Sachs RK, Hahnfeld P, Brenner DJ (1997) The link between low-LET dose-response relations and the underlying kinetics of damage production/repair/misrepair. Int J Radiat Biol 72:351–374
Lea DE, Catcheside DG (1942) The mechanism of the induction by radiation of chromosome abberations in tradescantia. J Genet 44:216–245
Barendson GW (1982) Dose fractionation, dose-rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 8:1981–1987
Fowler JF (1989) The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62:679–694
Bodey RK, Evans PM, Flux GD (2004) Application of the linear-quadratic model to combined modality radiotherapy. Int J Radiat Oncol Biol Phys 59(1):228–241
Pimblott SM, LaVerne JA (1997) Stochastic simulation of the electron radiolysis of water and aqueous solutions. J Phys Chem A 101:5828–5838
Becker D, Sevilla MD, Wang W, LaVere T (1997) The role of waters of hydration in direct-effect radiation damage to DNA. Radiat Res 148:508–510
Wright HA, Magee JL, Hamm RN, Chatterjee A, Turner JE, Klots CE (1985) Calculations of physical and chemical reactions produced in irradiated water containing DNA. Radiat Prot Dosimetry 13:133–136
Turner JE, Hamm RN, Ritchie RH, Bolch WE (1994) Monte Carlo track-structure calculations for aqueous solutions containing biomolecules. Basic Life Sci 63:155–166
Hall Eric J (2003) The Bystander effect. Health Phys 85(1):31–35
Maxon HR, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS et al (1992) Radioiodine-131 therapy for well-differentiated thyroid-cancer – a quantitative radiation dosimetric approach – outcome and validation in 85 patients. J Nucl Med 33(6):1132–1136
Maxon HR (1999) Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med 43(4):313–323
Kobe C, Eschner W, Sudbrock F, Weber I, Marx K, Dietlein M, Schicha H (2008) Graves’ disease and radioiodine therapy: is success of ablation dependent on the achieved dose above 200 Gy? Nuklearmedizin 47(1):13–17
Canzi C, Zito F, Voltini F, Reschini E, Gerundini P (2006) Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients. Med Phys 33(8):2860–2867
Carlier T, Salaun PY, Cavarec MB, Valette F, Turzo A, Bardies M, Bizais Y, Couturier O (2006) Optimized radioiodine therapy for Graves’ disease: two MIRD-based models for the computation of patient-specific therapeutic I-131 activity. Nucl Med Commun 27(7):559–566
Grosso M, Traino A, Boni G, Banti E, Della Porta M, Manca G, Volterrani D, Chiacchio S, AlSharif A, Borso E, Raschilla R, Di Martino F, Mariani G (2005) Comparison of different thyroid committed doses in radioiodine therapy for Graves’ hyperthyroidism. Cancer Biother Radiopharm 20(2):218–223
Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA (2003) Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose sing a risk-adapted approach. J Nucl Med 44:451–456
Jonsson H, Mattsson S (2004) Excess radiation absorbed doses from non-optimised radioiodine treatment of hyperthyroidism. Radiat Prot Dosim 108(2):107–114
Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, Krenning EP, Jamar F (2005) Practical dosimetry of peptide receptor radionuclide therapy with 90Y-labeled somatostatin analogs. J Nucl Med 46(1(Suppl)):92S–98S
Furhang EE, Larson SM, Buranapong P, Humm JL (1999) Thyroid cancer dosimetry using clearance fitting. J Nucl Med 40(1):131–136
Maxon HR, Thomas SR, Samaratunga RC (1997) Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid 7(2):183–187
Monsieurs M, Brans B, Bacher K, Dierckx R, Thierens H (2002) Patient dosimetry for I-131-MIBG therapy for neuroendocrine tumours based on I-123-MIBG scans. Eur J Nucl Med Mol Imaging 29(12):1581–1587
Flux GD, Guy MJ, Papavasileiou P, South C, Chittenden SJ, Flower MA, Meller ST (2003) Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG. Cancer Biother Radiopharm 18(1):81–87
DeNardo GL, DeNardo SJ, Shen S, DeNardo DA, Mirick GR, Macey DJ, Lamborn KR (1999) Factors affecting I-131-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. J Nucl Med 40(8):1317–1326
Linden O, Tennvall J, Cavallin-Stahl E, Darte L, Garkavij M, Lindner KJ, Ljungberg M, Ohlsson T, Sjogreen K, Wingardh K, Strand SE (1999) Radioimmunotherapy using I-131-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. Clin Cancer Res 5(10):3287S–3291S
Chatal JF, FaivreChauvet A, Bardies M, Peltier P, Gautherot E, Barbet J (1995) Bifunctional antibodies for radioimmunotherapy. Hybridoma 14(2):125–128
Wahl RL, Kroll S, Zasadny KR (1998) Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med 39(8):14S–20S
Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, Bartlett NL, Parker JA, Dunn WL, Spies SM, Belanger R, Witzig TE, Leigh BR (2001) Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin (TM) radioimmunotherapy for low-grade, follicular, or transformed B- cell non-Hodgkin’s lymphoma. Crit Rev Oncol Hematol 39(1–2):181–194
Cremonesi M, Ferrari M, Chinol M, Bartolomei M, Stabin MG, Sacco E, Fiorenza M, Tosi G, Paganelli G (2000) Dosimetry in radionuclide therapies with Y-90-conjugates: the IEO experience. Q J Nucl Med 44(4):325–332
Barone R, Walrand S, Valkema R, Kvols L, Smith C, Krenning EP, Jamar F, Pauwels S (2002) Correlation between acute red marrow (RM) toxicity and RM exposure during Y-90-SMT487 therapy. J Nucl Med 43:1267
Stabin MG (2008) The case for patient-specific dosimetry in radionuclide therapy. Cancer Biother Radiopharm 23(3): 273–284
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Berlin Heidelberg
About this chapter
Cite this chapter
Stabin, M.G. (2010). Radiobiology: Concepts and Basic Principles. In: Khalil, M. (eds) Basic Sciences of Nuclear Medicine. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-85962-8_9
Download citation
DOI: https://doi.org/10.1007/978-3-540-85962-8_9
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-85961-1
Online ISBN: 978-3-540-85962-8
eBook Packages: MedicineMedicine (R0)